Advaxis,
Inc.
(NASDAQ:ADXS), a late-stage biotechnology company focused
on the discovery, development and commercialization of immunotherapy
products, today announced that results from multiple preclinical studies
of its Lm-based antigen delivery technology will be presented at
the American Association for Cancer Research Annual Meeting 2018 (AACR
2018), April 14-18, 2018 in Chicago.
The following late-breaking research will be
